Monograph
A16AX05 - Zinc Acetate |
Not porphyrinogenic |
NP |
Rationale
There is no data indicating zinc acetate is interacting with CYP and it is therefore probably not porphyrinogenic.
Chemical description
Zinc salt
Therapeutic characteristics
Zinc acetate is indicated for the treatment of Wilson’s disease.
Metabolism and pharmacokinetics
Around 80% of zinc is bound to erythrocytes and the rest is mainly bound to albumin and other plasma proteins. The elimination of zinc results primarily from faecal excretion. The faecal excretion is in the greatest part due to the passage of unabsorbed zinc but it is also due to endogenous intestinal secretion.
Similar drugs
References
| # | Citation details | PMID |
|---|---|---|
| * | Summary of Product Characteristics | |
| 1. | The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). zinc acetate.
|
|
Tradenames
This list comprises raw data collected from different countries.
In some cases, a more comprehensive list of available drug packages is included.
Consequently, very similar terms may therefore appear multiple times.
Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Wilzin 
Wilzin 
Wilzin 
Wilzin 
Wilzin 
Wilzin 
Wilzin 
Wilzin 
Wilzin 
Wilzin 
Wilzin 
Wilzin 
Wilzin
© NAPOS 2025